Risk of de‐novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications
Open Access
- 21 April 2020
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (11), 1067-1075
- https://doi.org/10.1111/apt.15721
Abstract
Background An association between bariatric surgery and development of de‐novo inflammatory bowel disease (IBD) has been observed. Aim To evaluate further the association among bariatric surgery, weight loss medications, obesity and new‐onset IBD. Methods Using Explorys, a population‐based Health Insurance Portability and Accountability Act compliant database, we estimated the prevalence of de‐novo IBD among patients treated with bariatric surgery (Roux‐en‐Y gastrojejunostomy, laparoscopic sleeve gastrectomy or gastric banding) (n = 60 870) or weight loss medications (orlistat, phentermine/topiramate, lorcaserin, bupropion/naltrexone and liraglutide) (n = 193 790) compared with obese controls (n = 5 021 210), between 1999 and 2018. Results The prevalence of de‐novo IBD was lower among obese patients exposed to bariatric surgery (7.72 per 1000 patients) or weight loss medications (7.22 per 1000 patients) compared with patients with persistent obesity not exposed to these interventions (11.66 per 1000 patients, P < 0.0001). The risk reduction for de‐novo IBD was consistent across bariatric surgeries and weight loss medications with the exception of orlistat which was not associated with a reduction in risk for de‐novo IBD compared with the persistent obese control cohort. Conclusion Obese patients undergoing treatment with bariatric surgery or weight loss medications are at a lower risk for developing de‐novo IBD compared with persistently obese controls not exposed to these interventions. These data suggest that obesity and ineffective management of obesity are risk factors for de‐novo IBD. Further research is needed to confirm these observations and understand potential mechanisms.This publication has 24 references indexed in Scilit:
- Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohnʼs DiseaseInflammatory Bowel Diseases, 2017
- Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomesNature Reviews Gastroenterology & Hepatology, 2016
- Bariatric Surgery and Long-term Durability of Weight LossJAMA Surgery, 2016
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse EventsJAMA, 2016
- Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2014
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Mortality, Health Outcomes, and Body Mass Index in the Overweight RangeCirculation, 2009
- Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and AdultsGastroenterology, 2008
- Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk ReductionJAMA, 2005
- Practical statistics for medical research. Douglas G. Altman, Chapman and Hall, London, 1991. No. of pages: 611. Price: £32.00Statistics in Medicine, 1991